Cat. No. | Product name | CAS No. |
DC48355 |
Garsorasib
Garsorasib is a potent inhibitor of KRAS G12C with an IC50 of 10 nM. Garsorasib has the potential for the research of various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (non-small cell lung cancer) (extracted from patent WO2020233592A1, compound 2). |
2559761-14-5 |
DC48826 |
SOS1-IN-3
SOS1-IN-3 is a potent SOS1 (son of sevenless homolog 1) inhibitor with an IC50 of 5 nM. SOS1-IN-3 has anticancer effects (WO2019122129A1; compound I-1). |
2359689-76-0 |
DC48952 |
SOS1-IN-4
SOS1-IN-4 is a potent SOS1 inhibitor with an IC50 of 56 nM for KRAS-C12C/SOS1 interaction (WO2021228028 A1, example 65). |
2738392-83-9 |
DC49008 |
SOS1-IN-5
SOS1-IN-5 is a potent inhibitor of SOS1. SOS1-IN-5 is a pyrimidobicyclic derivative. SOS1-IN-5 blocks the activation of KRAS by interfering with RAS-SOS1 interaction, and achieves the purpose of broad-spectrum inhibition of KRAS activity. SOS1-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2021203768A1, compound 4). |
2716956-47-5 |
DC49060 |
KRAS G12C inhibitor 24
KRAS G12C inhibitor 24 is a potent KRAS G12C inhibitor. KRAS G12C inhibitor 24 inhibits KRAS G12C/SOS1 interaction with an IC50 of<50 nM (CN113563323A, compound 1). |
2735742-75-1 |
DC49086 |
KRAS G12C inhibitor 27
KRAS G12C inhibitor 27 is a KRAS G12C inhibitor with antitumor effects (WO2021109737). |
2648584-51-2 |
DC49087 |
KRAS G12C inhibitor 26
KRAS G12C inhibitor 26 is a KRAS G12C inhibitor with antitumor effects (WO2021109737). |
2648584-52-3 |
DC49132 |
KRAS G12C inhibitor 23
KRAS G12C inhibitor 23 is a KRAS G12C inhibitor. KRAS G12C inhibitor 23 inhibits H358 cells with an IC50 of 491 nM (WO2021218939A1, compound 1). |
2735721-00-1 |
DC49137 |
KRAS G12C inhibitor 25
KRAS G12C inhibitor 25 is a KRAS G12C inhibitor. KRAS G12C inhibitor 25 inhibits SOSl-assisted GDP/GTP exchanging activity of KRAS-G12C mutant (IC50=0.48 nM). From WO2021216770A1 compound 3. |
2734060-73-0 |
DC49138 |
KRAS G12C inhibitor 22
KRAS G12C inhibitor 22 is a KRAS G12C inhibitor extracted from patent WO2021219072A1, example 120. |
2736599-72-5 |
DC49148 |
KRAS G12C inhibitor 28
KRAS G12C inhibitor 28 is a KRAS G12C inhibitor with an IC50 of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1). |
2649004-88-4 |
DC49149 |
KRAS G12C inhibitor 20
KRAS G12C inhibitor 20 is a KRAS G12C inhibitor extracted from patent CN112694475A, example 1. |
2640858-10-0 |
DC49155 |
KRAS G12C inhibitor 21
KRAS G12C inhibitor 21 is a KRAS G12C inhibitor extracted from patent WO2021219090A1, example 7. |
2737269-61-1 |
DC50080 |
KRAS G12C inhibitor 29
KRAS G12C inhibitor 29 is a KRAS G12C inhibitor extracted from patent WO2021252339A1, compound 3. KRAS G12C inhibitor 29 can be used for the research of cancer. |
847337-63-7 |
DC50081 |
KRAS inhibitor-11
KRAS inhibitor-11 (compound 12) is a KRAS inhibitor. |
|
DC50082 |
K20
K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 µM. K20 shows anticancer activity in H358 cells (IC50= 0.78 µM). K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity. |
|
DC50083 |
KRAS G12D inhibitor 14
KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a KD of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D. |
|
DC70040 |
SOS1-IN-9
SOS1-IN-9 is a potent SOS1 inhibitor with an IC50 of 116.5 nM for SOS1-KRAS G12C (WO2022028506A1, compound 302). |
|
DC70041 |
SOS1-IN-10
SOS1-IN-10 is a potent SOS1 inhibitor with an IC50 of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8). |
|
DC70042 |
KRAS G12C inhibitor 32
KRAS G12C inhibitor 32, an eight membered heterocyclic compound containing N, is a potent KRAS G12C inhibitor. |
|
DC70043 |
ZINC09659342
ZINC09659342 (compound 13) is an inhibitor of Lbc-RhoA interaction with an IC50 of 3.6 μΜ. |
1668604-47-4 |
DC70044 |
KRAS G12C inhibitor 33
KRAS G12C inhibitor 33 is a KRAS G12C inhibitor extracted from patent WO2021244603A1, compound 1. KRAS G12C inhibitor 33 can be used for the research of cancer. |
2648985-02-6 |